Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00732056 | A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer | PHASE1 | COMPLETED | 24 | — | — | Jul 1, 2008 | Mar 1, 2012 | Dec 24, 2015 | 2 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | 3+3 cohort dose escalation |
| Name | Type | Description |
|---|---|---|
| GRN163L | DRUG | 25% dose escalation infused over 2 hours weekly |
Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the breast with measurable locally recurrent or metastatic disease * May have had one prior non-taxane chemotherapy regimen for metastatic disease * If HER2 positive, must have had prior treatment with trastuzumab (He...